Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Regenerative Medical Technology Group EV-to-EBIT?
Regenerative Medical Technology GroupRMTG +13.71% EV-to-EBIT is 24.88 as of Aug. 19, 2026. The stock has 4 warning signs investors should review. Among 369 Biotechnology companies, Regenerative Medical Technology Group ranks worse than 62.87% on this metric.
Regenerative Medical Technology Group (OTCPK:RMTG) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Regenerative Medical Technology Group's Enterprise Value for the quarter that ended in Mar. 2026 was $19.88 Mil.
Regenerative Medical Technology Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group EV-to-EBIT Related Terms
Regenerative Medical Technology Group EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group EV-to-EBIT Chart
For the Biotechnology subindustry, Regenerative Medical Technology Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerative Medical Technology Group EV-to-EBIT vs Biotechnology Industry
Regenerative Medical Technology Group's current Enterprise Value is $20.30 Mil.
Regenerative Medical Technology Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group (RMTG) has a EV-to-EBIT of 24.88 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Regenerative Medical Technology Group and its competitors. According to the industry distribution chart, Regenerative Medical Technology Group ranks #232 out of 369 companies in the Biotechnology industry, placing it in the top 62.9%.
Is Regenerative Medical Technology Group's EV-to-EBIT too high?
Regenerative Medical Technology Group's current EV-to-EBIT is 24.88. The Biotechnology industry median EV-to-EBIT is 15.95. Regenerative Medical Technology Group's value of 24.88 is 56% above this industry median. Based on the distribution chart, Regenerative Medical Technology Group ranks #232 out of 369 companies in the Biotechnology industry, which is below the industry midpoint.
How does Regenerative Medical Technology Group's EV-to-EBIT compare to ABPO and CLSDQ?
According to the Biotechnology industry distribution chart, Regenerative Medical Technology Group ranks #232 out of 369 companies for EV-to-EBIT. This places Regenerative Medical Technology Group in the lower half of its industry. The industry median EV-to-EBIT is 15.95. Regenerative Medical Technology Group's value of 24.88 is 56% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.95, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regenerative Medical Technology Group's current EV-to-EBIT of 24.88 is 56% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Regenerative Medical Technology Group and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenerative Medical Technology Group's current EV-to-EBIT is 24.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Fairly Valued. The stock's GF Value™ is $0.06, compared to a current price of $0.06 — trading 0.5% below its estimated fair value. The current EV-to-EBIT is 24.88 and 56% above the Biotechnology industry median of 15.95. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current EV-to-EBIT is 24.88 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RMTG has been successfully added to your 
